)
“The company plans to launch Ondensetron injections in two variants of 2 mg/mI in 2 ml single dosage vials and 20 ml multi dosage vials,” the company informed in a statement issued on Monday.
Claris looks at the market size of around US $ 49 million (approx. Rs 264 crore) in the US. Claris had recently received the USFDA approval for its manufacturing facility.
The injection is indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin, and for prevention of postoperative nausea and/or vomiting, the company stated in the statement.
Company now has nine ANDAs approved in its name across four molecules. Claris has a total filing of 30 ANDAs across 20 products.
Company shares closed negative on Monday with loss of over 5 per cent at Rs 183.5 on Bombay Stock Exchange (BSE).
